APPM Respipharm is a multi-component formaldehyde-inactivated whole-cell bacterial vaccine containing three strains of Actinobacillus pleuropneumoniae (serotypes 2, 9 and 11) and one strain of Pasteurella multocida (serotype A). The product is indicated for use in pigs (sows and weaned piglets) from 6 weeks of age, intended to induce active immunisation of sows and piglets against pleuropneumonia caused by Actinobacillus pleuropneumoniae and against secondary infection by Pasteurella multocida.
The marketing-authorisation holder, Pharmagal Bio s.r.o., submitted an application via mutual recognition for APPM Respipharm, on the basis of the marketing authorisation granted by Slovakia. The application was submitted in the framework of Article 32 of Directive 2001/82/EC, as amended, where the Reference Member State was Slovakia and the Concerned Member States were Poland and Spain.
The mutual recognition procedure started on 3 April 2008.
Due to concerns raised by Spain during the mutual recognition procedure that APPM Respipharm may pose a potentially serious risk to human or animal health or to the environment with respect to quality and efficacy of the product, the reference Member State, Slovakia, referred the matter to the Agency on 7 October 2008 under Article 33(4) of Directive 2001/82/EC.
The referral procedure started on 15 October 2008. The Committee appointed Dr Anna-Maria Brady as rapporteur and Dr Frédéric Descamps as co-rapporteur. Written explanations were provided by the marketing-authorisation holder on 14 January 2009 and supplementary information was submitted on 22 April 2009.
Based on the evaluation of the rapporteur's assessment of the currently available data, the CVMP considered that the application does not satisfy the criteria for authorisation in respect of efficacy.
Therefore, the Committee adopted an opinion on 15 July 2009 recommending the suspension of the existing marketing authorisation and the refusal of the granting of the marketing authorisations for APPM Respipharm.
On 28 July 2009, Pharmagal Bio s.r.o. notified the Agency of its intention to request the reexamination of the CVMP opinion of 15 July 2009. The detailed grounds for the re-examination were submitted by Pharmagal Bio s.r.o. on 14 September 2009.
During its 15-17 September 2009 meeting, the CVMP appointed Dr Kristina Lehmann as rapporteur and Prof. Tibor Soós as co-rapporteur for the re-examination of the abovementioned opinion.
The re-examination procedure started on 15 September 2009.
Based on the evaluation of the rapporteur's assessment of the currently available data, the CVMP considered that its opinion of 15 July 2009 should not be revised, and therefore adopted an opinion on 11 November 2009 recommending the suspension of the existing Marketing Authorisation and the refusal of the granting of the Marketing Authorisations for APPM Respipharm.
The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II.
The final opinion was converted into a Decision by the European Commission on 27 January 2010.
|International non-proprietary name (INN) or common name||
formaldehyde-inactivated whole-cell bacterial vaccine containing three strains of Actinobacillus pleuropneumoniae (serotypes 2, 9 and 11) and one strain of Pasteurella multocida (serotype A)
European Commission final decision
Mutual-recognition and decentralised referral: initiated because of disagreement between Member States within the framework of the mutual-recognition or decentralised procedure.
|EC decision date||
Opinion following an Article 33(4) referral for APPM Respipharm: Background information (PDF/92.69 KB)Adopted
First published: 20/02/2010
Last updated: 20/02/2010
APPM Respipharm - Article 33 Referral - Annexes I, II, III (PDF/102.33 KB)Adopted
First published: 25/02/2010
Last updated: 25/02/2010
Description of documents published
Please note that some of the listed documents apply only to certain procedures.
- Overview - lay-language summary of the stage of the procedure
- Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
- List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
- Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
- List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
- List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. veterinary healthcare professionals, farmers, academia) (if applicable)
- Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
- Scientific conclusions – scientific conclusions of CVMP
- Divergent positions – divergent positions of the CVMP members (if applicable)
- Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
- Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
- Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)